Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis
Authors
Keywords
-
Journal
BMJ Evidence-Based Medicine
Volume -, Issue -, Pages bmjebm-2020-111634
Publisher
BMJ
Online
2021-10-12
DOI
10.1136/bmjebm-2020-111634
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge
- (2020) Giuseppe Lippi et al. International Journal of Stroke
- A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa
- (2020) Jerome Roy Semakula et al. PLoS One
- Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry
- (2020) Rungroj Krittayaphong et al. Journal of Clinical Medicine
- Systematic Review and Meta-analysis of Cost-effectiveness of Rotavirus Vaccine in Low and Low-Middle Income Countries
- (2019) Sabbir Haider et al. Open Forum Infectious Diseases
- 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
- (2019) Craig T. January et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation
- (2019) Piyameth Dilokthornsakul et al. Heart Lung and Circulation
- Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
- (2019) Ahmad S. Hersi et al. ANNALS OF SAUDI MEDICINE
- Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
- (2019) Lisa A. de Jong et al. PLoS One
- Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis
- (2019) Yi-Hsin Chan et al. CARDIOVASCULAR DRUGS AND THERAPY
- Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting
- (2019) Masatsugu Hori et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-effectiveness of warfarin care bundles and novel oral anticoagulants for stroke prevention in patients with atrial fibrillation in Thailand
- (2019) Siok Shen Ng et al. THROMBOSIS RESEARCH
- Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis
- (2019) Bhavani Shankara Bagepally et al. VALUE IN HEALTH
- Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding
- (2018) Alexa R. Hospodar et al. American Journal of Cardiovascular Drugs
- Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015
- (2018) Daehoon Kim et al. HEART
- ¿El uso de edoxabán sería coste-efectivo para la prevención del ictus y la embolia sistémica en pacientes con fibrilación auricular no valvular en España?
- (2018) Iñaki Lekuona et al. REVISTA ESPANOLA DE CARDIOLOGIA
- Antithrombotic Therapy for Atrial Fibrillation
- (2018) Gregory Y.H. Lip et al. CHEST
- Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function
- (2018) Jonathan Salcedo et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding
- (2018) Thananan Rattanachotphanit et al. PHARMACOECONOMICS
- Latin American Clinical Epidemiology Network Series – Paper 2: Apixaban was cost-effective vs. acenocoumarol in patients with nonvalvular atrial fibrillation with moderate to severe risk of embolism in Chile
- (2017) Fernando Lanas et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function
- (2017) Inmaculada Hernandez et al. THROMBOSIS RESEARCH
- Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
- (2017) José A López-López et al. BMJ-British Medical Journal
- Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
- (2017) José A López-López et al. BMJ-British Medical Journal
- The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands
- (2017) Marinus van Hulst et al. JOURNAL OF MEDICAL ECONOMICS
- Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective
- (2017) Patricia A. Cowper et al. JAMA Cardiology
- The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis
- (2017) Anne Sig Vestergaard et al. PLoS One
- Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥65 Years With Nonvalvular Atrial Fibrillation
- (2016) Brian M. Salata et al. AMERICAN JOURNAL OF CARDIOLOGY
- Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
- (2016) Kostas Athanasakis et al. American Journal of Cardiovascular Drugs
- Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
- (2016) Chieh-Yu Liu et al. CLINICAL DRUG INVESTIGATION
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
- (2016) Paulus Kirchhof et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation
- (2016) Ying Jiao Zhao et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients
- (2016) Elaine Nguyen et al. PHARMACOTHERAPY
- Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
- (2016) Anuj Shah et al. STROKE
- Consequências clínicas e económicas da utilização de dabigatrano e de rivaroxabano em doentes com fibrilhação auricular não valvular
- (2016) Luís Silva Miguel et al. Revista Portuguesa de Cardiologia
- Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
- (2016) Taru Hallinen et al. SpringerPlus
- Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry
- (2016) Sylvia Haas et al. PLoS One
- Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF–TIMI 48 trial
- (2015) Elizabeth A. Magnuson et al. AMERICAN HEART JOURNAL
- Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist
- (2015) Misericòrdia Carles et al. BMC HEALTH SERVICES RESEARCH
- Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting
- (2015) Kostas Athanasakis et al. CLINICAL DRUG INVESTIGATION
- Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation
- (2015) Gregory Y.H. Lip et al. CLINICAL THERAPEUTICS
- Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan
- (2015) Isao Kamae et al. CLINICAL THERAPEUTICS
- Meta-analysis in clinical trials revisited
- (2015) Rebecca DerSimonian et al. Contemporary Clinical Trials
- Análisis coste-efectividad de apixabán frente a acenocumarol en la prevención del ictus en pacientes con fibrilación auricular no valvular en España
- (2015) Gonzalo Barón Esquivias et al. REVISTA ESPANOLA DE CARDIOLOGIA
- Risk of bias in model-based economic evaluations: the ECOBIAS checklist
- (2015) Charles Christian Adarkwah et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Custo‐efetividade dos novos anticoagulantes orais na fibrilhação auricular em Portugal
- (2015) João Costa et al. Revista Portuguesa de Cardiologia
- Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
- (2015) Martin Krejczy et al. Biomed Research International
- Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies
- (2015) Carlos Crespo et al. BMC Medical Research Methodology
- Cost-Effectiveness of Apixaban Compared to Other New Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation
- (2015) A.V. Rudakova Rudakova et al. KARDIOLOGIYA
- Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups
- (2014) Andreas Clemens et al. AMERICAN JOURNAL OF CARDIOLOGY
- Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings
- (2014) Talitha I. Verhoef et al. American Journal of Cardiovascular Drugs
- Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective
- (2014) Julie Chevalier et al. Archives of Cardiovascular Diseases
- Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
- (2014) Ye Wang et al. CARDIOVASCULAR DRUGS AND THERAPY
- Contemporary Trends of Hospitalization for Atrial Fibrillation in the United States, 2000 Through 2010
- (2014) Nileshkumar J. Patel et al. CIRCULATION
- Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin
- (2014) Thitima Kongnakorn et al. CLINICAL DRUG INVESTIGATION
- Cost-Utility Analysis of Oral Anticoagulants for Nonvalvular Atrial Fibrillation Patients at the Police General Hospital, Bangkok, Thailand
- (2014) Siriporn Jarungsuccess et al. CLINICAL THERAPEUTICS
- Comparison of the Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation in a UK Setting
- (2014) Ying Zheng et al. CLINICAL THERAPEUTICS
- Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
- (2014) Gregory Y.H. Lip et al. CLINICAL THERAPEUTICS
- Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
- (2014) P. Dorian et al. EUROPEAN HEART JOURNAL
- Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
- (2014) Carla Rognoni et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation
- (2014) Alexander Mensch et al. PHARMACOECONOMICS
- Cost Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Depending on the Quality of Warfarin Anticoagulation Control
- (2014) Andrej Janzic et al. PHARMACOECONOMICS
- Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
- (2014) Torbjørn Wisløff et al. PHARMACOECONOMICS
- Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
- (2014) Jelena Stevanović et al. PLoS One
- Cost-effectiveness of Apixaban versus Warfarin and Aspirin in Sweden for Stroke Prevention in Patients with Atrial Fibrillation
- (2014) Tereza Lanitis et al. THROMBOSIS RESEARCH
- Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan
- (2014) Chia-Hsien Chang et al. THROMBOSIS RESEARCH
- Cost-Effectiveness Of Apixaban Compared To Warfarin And Aspirin In Patients With Non-Valvular Atrial Fibrillation (Nvaf) In The Russian Federation
- (2014) A.V. Rudakova et al. VALUE IN HEALTH
- Cost Effectiveness Analysis Of Apixaban Versus Other Noacs For The Prevention Of Stroke In Italian Non-Valvular Atrial Fibrillation Patients
- (2014) L. Pradelli et al. VALUE IN HEALTH
- Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting
- (2014) João Morais et al. Revista Portuguesa de Cardiologia
- Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin
- (2014) T. Lanitis et al. JOURNAL OF MEDICAL ECONOMICS
- Epidemiology of atrial fibrillation: European perspective
- (2014) Massimo Zoni-Berisso et al. Clinical Epidemiology
- Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
- (2013) James V. Freeman et al. ANNALS OF INTERNAL MEDICINE
- Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation
- (2013) Anuraag R. Kansal et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Cost–Effectiveness of Different Strategies for Stroke Prevention in Patients with Atrial Fibrillation in a Health Resource-Limited Setting
- (2013) Bin Wu et al. CARDIOVASCULAR DRUGS AND THERAPY
- Worldwide Epidemiology of Atrial Fibrillation
- (2013) Sumeet S. Chugh et al. CIRCULATION
- Cost-Effectiveness of Oral Anticoagulants for Treatment of Atrial Fibrillation
- (2013) William J. Canestaro et al.
- Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
- (2013) Carla Rognoni et al. CLINICAL DRUG INVESTIGATION
- Comparative Effectiveness of Dabigatran, Rivaroxaban, Apixaban, and Warfarin in the Management of Patients With Nonvalvular Atrial Fibrillation
- (2013) J Pink et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Cost-Effectiveness of Pharmacogenetics-Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation
- (2013) J Pink et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Novel Oral Anticoagulants Versus Warfarin Therapy at Various Levels of Anticoagulation Control in Atrial Fibrillation—A Cost-Effectiveness Analysis
- (2013) Joyce H. S. You JOURNAL OF GENERAL INTERNAL MEDICINE
- Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries
- (2013) Martin Krejczy et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
- (2013) Christian T Ruff et al. LANCET
- Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
- (2013) Joris Kleintjens et al. PHARMACOECONOMICS
- A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation
- (2013) Sonja V. Sorensen et al. PHARMACOECONOMICS
- Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Cost-Effectiveness Models
- (2013) Brendan L. Limone et al. PLoS One
- Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
- (2013) Amanda R. Harrington et al. STROKE
- Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation
- (2013) Doug Coyle et al. VALUE IN HEALTH
- Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia
- (2013) Zanfina Ademi et al. European Journal of Preventive Cardiology
- Avaliação económica do dabigatrano na prevenção de acidentes vasculares cerebrais isquémicos em doentes com fibrilhação auricular não valvular
- (2013) Luís Silva Miguel et al. Revista Portuguesa de Cardiologia
- Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial
- (2013) Daniel E. Singer et al. Journal of the American Heart Association
- Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide
- (2013) Louise Justesen Hesselbjerg et al. JOURNAL OF MEDICAL ECONOMICS
- Cost–Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
- (2012) Soyon Lee et al. AMERICAN JOURNAL OF CARDIOLOGY
- Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
- (2012) Thomas Davidson et al. EUROPEAN HEART JOURNAL
- Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
- (2012) Anuraag R Kansal et al. HEART
- Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation
- (2012) H. Kamel et al. NEUROLOGY
- Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
- (2012) Soyon Lee et al. PLoS One
- Análisis coste-efectividad de dabigatrán para la prevención de ictus y embolia sistémica en fibrilación auricular no valvular en España
- (2012) José R. González-Juanatey et al. REVISTA ESPANOLA DE CARDIOLOGIA
- Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
- (2012) Hooman Kamel et al. STROKE
- Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada
- (2012) Michael Sharma et al. THROMBOSIS AND HAEMOSTASIS
- Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark
- (2012) Lars K Langkilde et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation
- (2011) Shimoli V. Shah et al. CIRCULATION
- Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective
- (2011) Anuraag Kansal et al. THROMBOSIS AND HAEMOSTASIS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now